What is the translation of " MYELOSUPPRESSION " in English?

• myelosuppression
• myelosupression

Examples of using Myelosuppression in Danish and their translations into English

Myelosuppression er derfor almindelig.
Myelosuppression is thus common.

Basiliximab forårsager ikke myelosuppression.
Basiliximab does not cause myelosuppression.

Myelosuppression er normalt den dosisbegrænsende toksicitet.
Myelosuppression is usually the dose-limiting toxicity.

Lungeemboli eller alvorlig myelosuppression.
Pulmonary embolism or severe myelosuppression.

Myelosuppression var for det meste mild eller moderat og let at styre.
Myelosuppression was mostly mild or moderate and manageable.

Forbundet med forsinket myelosuppression for eksempel nitrosourea. læ.
Associated with delayed myelosuppression e. g., nitrosoureas. tn uc.

Myelosuppression Behandling med Myocet forårsager myelosuppression.
Myelosuppression Therapy with Myocet causes myelosuppression.

Som for andre cytostatika kan topotecan forårsage svær myelosuppression.
As with other cytotoxic medicinal products, topotecan can cause severe myelosuppression.

Vedvarende alvorlig myelosuppression kan medføre superinfektion eller blødning.
Persistent severe myelosuppression, may result in superinfection or haemorrhage.

De fleste patienter fortsatte behandling uden yderligere tegn på myelosuppression.
Most patients continued treatment without further evidence of myelosuppression.

Restitution efter myelosuppression sker normalt hurtigt, når behandlingen seponeres.
Recovery from myelosuppression is usually rapid when therapy is discontinued.

Hvis antallet af visse former for blodceller er svært nedsat(myelosuppression), såsom antallet af.
If certain kinds of blood cells are severely reduced(myelosuppression), such as your white blood.

Infektioner Myelosuppression kan føre til neutropeni og forøget infektionsrisiko.
Infections Myelosupression may lead to neutropenia and an increased risk of infection.

Patienter med nedsat leverfunktion kan eventuelt have øget risiko for toksicitet, især grad 3- 4 myelosuppression.
Patients with hepatic impairment may be at increased risk of toxicity, particularly Grade 3-4 myelosuppression.

Hos patienter med resistent myelosuppression anvendtes hæmatopoetisk vækstfaktor.
Haematopoetic growth factor has been used in patients with resistant myelosuppression.

Myelosuppression og levertoksicitet blev identificeret som den primære toksicitet i forbindelse med trabectedin.
Myelosupression and hepatoxicity were identified as the primary toxicity for trabectedin.

Meget almindelige: pancytopeni/ myelosuppression*, purpura Almindelige: petecchier, blødninger.
Very common: pancytopenia/ myelosuppression*, purpura Common: petechiae, haemorrhages.

Myelosuppression og immunosuppression var den ønskede terapeutiske effekt af den konditionerende behandling.
Myelo-suppression and immuno-suppression were the desired therapeutic effects of the conditioning regimen.

Den hyppigst indberettede bivirkning er myelosuppression med neutropeni som den mest almindelige manifestation.
The most frequently reported adverse reaction is myelosuppression with neutropenia as the most common manifestation.

Myelosuppression er dog kortvarig og fører normalt ikke til dosisreduktion og sjældent til seponering.
However, myelosuppression is short lived and usually does not result in dose reduction and rarely in discontinuation.

Temodal må ikke anvendes til patienter med svær myelosuppression en tilstand, hvor knoglemarven ikke kan producere nok blodceller.
Temodal must not be used in patients with severe myelosuppression a condition in which the bone marrow cannot make enough blood cells.

Varsomhed skal ligeledes iagttages hos patienter med koagulationsforstyrrelser(såsom thrombophlebitis, lungeemboli) eller alvorlig myelosuppression.
Caution must be observed also in patients with coagulation disorders(e. g., thrombophlebitis, pulmonary embolism) or severe myelosuppression.

I kliniske forsøg er myelosuppression blevet behandlet med dosisafbrydelse, dosisreduktion eller seponering af forsøgsbehandling.
In clinical trials, myelosuppression was managed by dose interruption, dose reduction, or discontinuation of study therapy.

Ved indgivelse som længerevarende infusion kan der forekomme øget myelosuppression hos patienter med moderat til svært nedsat leverfunktion.
When given as a longer infusion, increased myelosuppression may be seen in patients with moderate to severe hepatic impairment.

I dyremodeller er samtidig administration af Neulasta og 5- fluorouracil(5- FU) eller andre antimetabolitter blevet vist at øge myelosuppression.
In animal models concomitant administration of Neulasta and 5-fluorouracil(5-FU) or other antimetabolites has been shown to potentiate myelosuppression.

Når paclitaxel blev givet efter cisplatin, udviste patienterne en mere udtalt myelosuppression og et cirka 20% fald i paclitaxel clearance.
When paclitaxel was given after cisplatin, patients showed a more profound myelosuppression and an approximately 20% decrease in paclitaxel clearance.

Myelosuppression(neutropeni og trombocytopeni), som er en kendt dosisbegrænsende toksicitet for de fleste cytotoksiske stoffer, inklusive TMZ, blev observeret.
Myelosuppression(neutropenia and thrombocytopenia), which is known dose-limiting toxicity for most cytotoxic agents, including TMZ, was observed.

Det er sandsynligt, at en overdosis af nelarabin vil resultere i svær neurotoksicitet(muligvis inkl. paralyse, coma), myelosuppression og potentielt død.
It is likely that nelarabine overdose would result in severe neurotoxicity(possibly including paralysis, coma), myelosuppression and potentially death.

Myelosuppression associeret med anæmi, thrombocytopeni, leukopeni og sjældent febril neutropeni, har været rapporteret hos patienter behandlet med Caelyx.
Myelosuppression associated with anaemia, thrombocytopaenia, leukopaenia, and rarely febrile neutropaenia, has been reported in Caelyx-treated patients.

Hæmatologi I den første måned efter behandling er myelosuppression yderst vigtig, og det kan blive nødvendigt med transfusioner af røde blodlegemer eller trombocytter.
Haematology During the first month following treatment, myelosuppression is most notable and red blood cell or platelet transfusions may be required.

How to use "myelosuppression" in a Danish sentence

Ved grad 2-anomalier forekom der forværring af myelosuppression hos de fleste patienter og hyppigere end hos patienter med anomalier af grad 1 eller 0 ved baseline.

Neuroadfærdsmæssig udvikling og reproduktionsevne blev ikke påvirket, når neonatale/juvenile rotter blev behandlet ved dosisniveauer, der inducerede myelosuppression.

Myelosuppression og komplikationer af myelosuppression, herunder infektioner og blødninger, der forekommer hos patienter med AML, kan forværres ved behandling med Dacogen.

Vigtige sikkerhedsoplysninger for ALIMTA Myelosuppression er sædvanligvis den dosisbegrænsende toksicitet ved ALIMTA-terapi.

Processer, som kan forårsage myelosuppression omfatter: Kemoterapi-induceret knoglemarvsdepression.

I tilfælde af myelosuppression eller dets komplikationer kan behandling med Dacogen afbrydes, og/eller der kan iværksættes understøttende behandling (se pkt. 4.2 og 4.8).

Behandling med Cyclophosphamid i stedet for Melphalan anbefales ved neutrofiltal < 1.0 x 10 9 /L eller trombocyttal < 75 x 10 9 /L, idet Cyclophosphamid giver korterevarende myelosuppression.

Toksicitet vil sandsynligvis manifestere sig som forværring af bivirkninger, primært myelosuppression.

Hvis samtidig administration af et NSAID er nødvendigt, bør patienterne monitoreres nøje for toksicitet, især myelosuppression, nyre- og gastrointestinale toksiciteter.

Komplikationer ved myelosuppression omfatter infektioner og blødning.

How to use "myelosuppression" in an English sentence

Severe myelosuppression is the anticipated effect following overdose.

Significant myelosuppression did not occur in any patient.

PubMed:Protection against cyclophosphamide-induced myelosuppression by ZPDC glycoprotein (24 kDa).

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.

Toxicity consisted mainly of myelosuppression and gastrointestinal side effects.

Toxicity included diarrhea and myelosuppression in 6 pts (50%).

Severe late myelosuppression has also been seen occasionally.

The agents utilized have myelosuppression as their dose-limiting toxicity.

Major treatment toxicities were myelosuppression and infections.

Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant patients.